Long-acting injectable antivirals transforming HIV and hepatitis management — the cabotegravir/rilpivirine monthly and every-two-months regimen reducing pill burden while maintaining viral suppression, alongside emerging lenacapavir semiannual injections for multidrug-resistant HIV — represent the most patient-centric innovation in antiviral therapy since the protease inhibitor era,...